These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

378 related items for PubMed ID: 12599570

  • 1. [Total androgen blockade].
    Namiki M, Mizokami A.
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():193-8. PubMed ID: 12599570
    [No Abstract] [Full Text] [Related]

  • 2. Re: The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
    Gardiner RA, Nicol DL, Green HJ, Yaxley J, Watson R, Mactaggart P, Headley BC, Swanson C, Pakenham KI.
    J Urol; 2004 Aug; 172(2):774; author reply 774-5. PubMed ID: 15247782
    [No Abstract] [Full Text] [Related]

  • 3. [Antiandrogen in prostate cancer].
    Maeda O, Usami M.
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():188-92. PubMed ID: 12599569
    [No Abstract] [Full Text] [Related]

  • 4. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
    Nishimura K, Arichi N, Tokugawa S, Yoshioka I, Kishikawa H, Ichikawa Y.
    Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
    [Abstract] [Full Text] [Related]

  • 5. [Endocrine therapy for prostate cancer in the future].
    Usami M.
    Gan To Kagaku Ryoho; 1998 May; 25(6):817-22. PubMed ID: 9617319
    [Abstract] [Full Text] [Related]

  • 6. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM, Torréns JI, Harding P, Howard RS, Duncan WE, McLeod DG.
    Prostate Cancer Prostatic Dis; 2002 May; 5(4):304-10. PubMed ID: 12627216
    [Abstract] [Full Text] [Related]

  • 7. Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer.
    Moul JW.
    Cancer; 2009 Aug 01; 115(15):3376-8. PubMed ID: 19484788
    [No Abstract] [Full Text] [Related]

  • 8. Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences.
    Collette L, Studer UE, Schröder FH, Denis LJ, Sylvester RJ.
    Prostate; 2001 Jun 15; 48(1):29-39. PubMed ID: 11391684
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Leuprorelin, triptorelin: new indications. Locally advanced prostate cancer: minimally assessed me-toos.
    Prescrire Int; 2007 Dec 15; 16(92):243. PubMed ID: 18092407
    [Abstract] [Full Text] [Related]

  • 12. [Reevaluation of MAB therapy and progress of endocrine therapy].
    Klotz L, Payne H, Gillatt D, Keane T, Morris C, Akaza H, Hirao, Akakura K, Fukagai T.
    Gan To Kagaku Ryoho; 2005 May 15; 32(5):705-28. PubMed ID: 15934164
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer.
    Blackledge G, Kolvenbag G, Nash A.
    Anticancer Drugs; 1996 Jan 15; 7(1):27-34. PubMed ID: 8742095
    [Abstract] [Full Text] [Related]

  • 15. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group.
    Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Sarosdy MF, Vogelzang NJ, Chen Y, Kolvenbag GJ.
    Cancer; 1996 Nov 15; 78(10):2164-9. PubMed ID: 8918410
    [Abstract] [Full Text] [Related]

  • 16. The place and the results of monotherapy.
    Bonnet P.
    Acta Urol Belg; 1998 May 15; 66(2):11-5. PubMed ID: 9633120
    [No Abstract] [Full Text] [Related]

  • 17. Combined androgen blockade: leuprolide and flutamide versus leuprolide and placebo.
    Crawford ED, Goodman P, Blumenstein B.
    Semin Urol; 1990 Aug 15; 8(3):154-8. PubMed ID: 2119048
    [No Abstract] [Full Text] [Related]

  • 18. Maximal androgen blockade (MAB) for the treatment of prostate cancer.
    Kirby RS.
    Br J Clin Pract; 1996 Aug 15; 50(5):287. PubMed ID: 8794610
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Hormonal treatment of cancer of the prostate: review and present status].
    Ganzer R, Wieland WF, Bach T, Rössler W, Blana A.
    Dtsch Med Wochenschr; 2007 Jan 26; 132(4):161-6. PubMed ID: 17230333
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.